Figure 1.

Screening of cell surface molecules to target monocytic progenitors. (A) Screening scheme for molecules highly restricted in monocytic progenitors. The expression of 361 cell surface molecules on HSPCs derived from UCB were examined using FCM. Expression of candidates identified from HSPC screening was further assessed on mature hematopoietic cell lineages. (B) Gating strategies for hematopoietic progenitors in UCB. Lineage^- cells (Lin^- cells; CD2^-CD3^-CD11b^-CD14^-CD16^-CD19^-CD56^-CD235ab^- cells) were pre-gated. Gating strategies of other HSPCs are shown in Supplementary Figure 1A . (C–F) Expression of CD64 on mature hematopoietic cells and their progenitors. CD64 expression was evaluated on monocytic progenitors (C), monocytes (D), non-monocytic immune cells (E) and the other hematopoietic stem and progenitor cells (F) by FCM. Each population was identified by the following gating strategies: B cell, FSC^loSSC^loCD3^-CD56^-CD19⁺; T cell, FSC^loSSC^loCD3⁺; NK cell, FSC^loSSC^loCD56⁺CD3^-; Neutrophil, SSC^hiHLA-DR^-CD66b⁺CD16⁺; pDC, CD3^-CD14^-CD19^-CD56^-CD11c^-HLA-DR⁺CD123⁺; cDC, CD3^-CD14^-CD19^-CD56^-CD123^-HLA-DR⁺CD11c⁺. Blood monocytes (HLA-DR⁺CD14⁺) were subdivided into three populations based on their expression of CD14 and CD16 as shown in (D, left panel). The data are representative of three independent experiments.